{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:41:08Z","timestamp":1760298068271},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,3,26]],"date-time":"2009-03-26T00:00:00Z","timestamp":1238025600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1245\/s10434-009-0436-2","type":"journal-article","created":{"date-parts":[[2009,3,25]],"date-time":"2009-03-25T14:57:10Z","timestamp":1237993030000},"page":"1771-1782","source":"Crossref","is-referenced-by-count":71,"title":["Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical Practice"],"prefix":"10.1245","volume":"16","author":[{"given":"Dimosthenis","family":"Ziogas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios H.","family":"Roukos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,26]]},"reference":[{"issue":"2","key":"436_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71\u201396.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"436_CR2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ncponc0930","volume":"4","author":"DH Roukos","year":"2007","unstructured":"Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol. 2007;4(10):578\u201390.","journal-title":"Nat Clin Pract Oncol"},{"issue":"15","key":"436_CR3","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJMc072301","volume":"357","author":"DH Roukos","year":"2007","unstructured":"Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357(15):1555\u20136.","journal-title":"N Engl J Med"},{"key":"436_CR4","doi-asserted-by":"crossref","unstructured":"My genome. So, what. Nature. 2008;6;456(7218):1. Editorial.","DOI":"10.1038\/456001a"},{"issue":"7218","key":"436_CR5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","volume":"456","author":"TJ Ley","year":"2008","unstructured":"Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218):66\u201372.","journal-title":"Nature"},{"issue":"1","key":"436_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/14737159.9.1.1","volume":"9","author":"DH Roukos","year":"2009","unstructured":"Roukos DH. Assessing both genetic variation (SNPs\/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn. 2009;9(1):1\u20136.","journal-title":"Expert Rev Mol Diagn"},{"issue":"Suppl 1","key":"436_CR7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/1097-0142(197707)40:1+<574::AID-CNCR2820400724>3.0.CO;2-O","volume":"40","author":"B Fisher","year":"1977","unstructured":"Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. Cancer. 1977;40(Suppl 1):574\u201387.","journal-title":"Cancer"},{"key":"436_CR8","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","volume":"366","author":"M Clarke","year":"2005","unstructured":"Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087\u2013106.","journal-title":"Lancet"},{"issue":"23","key":"436_CR9","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMra065241","volume":"356","author":"RS Punglia","year":"2007","unstructured":"Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med. 2007;356(23):2399\u2013405.","journal-title":"N Engl J Med"},{"key":"436_CR10","doi-asserted-by":"crossref","unstructured":"Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists\u2019 Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45\u201353.","DOI":"10.1016\/S1470-2045(07)70385-6"},{"key":"436_CR11","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. N Engl J Med. 2005;353:1659\u201372.","journal-title":"N Engl J Med"},{"key":"436_CR12","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med. 2005;353:1673\u201384.","journal-title":"N Engl J Med"},{"issue":"11","key":"436_CR13","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1245\/s10434-008-0129-2","volume":"15","author":"IL Wapnir","year":"2008","unstructured":"Wapnir IL, Aebi S, Gelber S, Anderson SJ, L\u00e1ng I, Robidoux A, et al. Progress on BIG 1-02\/IBCSG 27-02\/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer. Ann Surg Oncol. 2008;15(11):3227\u201331.","journal-title":"Ann Surg Oncol"},{"key":"436_CR14","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1200\/JCO.2007.12.3141","volume":"25","author":"TM Tuttle","year":"2007","unstructured":"Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203\u20139.","journal-title":"J Clin Oncol"},{"key":"436_CR15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.radonc.2008.01.013","volume":"86","author":"DH Roukos","year":"2008","unstructured":"Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol. 2008;86:139\u201341.","journal-title":"Radiother Oncol"},{"issue":"7","key":"436_CR16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","volume":"18","author":"A Goldhirsch","year":"2007","unstructured":"Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):1133\u201344.","journal-title":"Ann Oncol"},{"issue":"3","key":"436_CR17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4161\/cbt.6.3.3994","volume":"6","author":"DH Roukos","year":"2007","unstructured":"Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther. 2007;6(3):308\u201312.","journal-title":"Cancer Biol Ther"},{"issue":"5853","key":"436_CR18","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1126\/science.1145720","volume":"318","author":"LD Wood","year":"2007","unstructured":"Wood LD, Parsons DW, Jones S, Lin J, Sj\u00f6blom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108\u201313.","journal-title":"Science"},{"key":"436_CR19","doi-asserted-by":"crossref","unstructured":"International HapMap Consortium, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. A second generation human haplotype map of over 3.1\u00a0million SNPs. Nature. 2007;449(7164):851\u201361.","DOI":"10.1038\/nature06258"},{"issue":"7","key":"436_CR20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMcibr0708452","volume":"358","author":"C Lee","year":"2008","unstructured":"Lee C, Morton CC. Structural genomic variation and personalized medicine. N Engl J Med. 2008;358(7):740\u20131.","journal-title":"N Engl J Med"},{"key":"436_CR21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1126\/science.1149504","volume":"318","author":"JO Korbel","year":"2007","unstructured":"Korbel JO, Urban AE, Affourtit JP, Godwin B, Grubert F, Simons JF, et al. Paired-end mapping reveals extensive structural variation in the human genome. Science. 2007;318:420\u20136.","journal-title":"Science"},{"issue":"5858","key":"436_CR22","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1126\/science.318.5858.1842","volume":"318","author":"E Pennisi","year":"2007","unstructured":"Pennisi E. Breakthrough of the year human genetic variation. Science. 2007;318(5858):1842\u20133.","journal-title":"Science"},{"issue":"7148","key":"436_CR23","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/nature05887","volume":"447","author":"DF Easton","year":"2007","unstructured":"Easton DF, Pooley KA, Dunning AM. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087\u201393.","journal-title":"Nature"},{"issue":"11","key":"436_CR24","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1073\/pnas.0800441105","volume":"105","author":"B Gold","year":"2008","unstructured":"Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, et al. Genome-wide association study provides evidence for a breast cancer risk locus at 6q2233. Proc Natl Acad Sci USA. 2008;105(11):4340\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"436_CR25","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ng2075","volume":"39","author":"DJ Hunter","year":"2007","unstructured":"Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39:870\u20134.","journal-title":"Nat Genet"},{"issue":"7171","key":"436_CR26","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nature06358","volume":"450","author":"BA Weir","year":"2007","unstructured":"Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007;450(7171):893\u20138.","journal-title":"Nature"},{"issue":"9","key":"436_CR27","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJMoa075819","volume":"358","author":"SL Zheng","year":"2008","unstructured":"Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910\u20139.","journal-title":"N Engl J Med"},{"issue":"14","key":"436_CR28","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","volume":"26","author":"PL Nguyen","year":"2008","unstructured":"Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373\u20138.","journal-title":"J Clin Oncol"},{"key":"436_CR29","doi-asserted-by":"crossref","unstructured":"Kyndi M, S\u00f8rensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419\u201326.","DOI":"10.1200\/JCO.2007.14.5565"},{"key":"436_CR30","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.2007.16.0192","volume":"26","author":"MJ Hooning","year":"2008","unstructured":"Hooning MJ, Aleman BM, Hauptmann M, Baaijens MH, Klijn JG, Noyon R, et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol. 2008;26:5561\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"436_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2008.08.005","volume":"90","author":"BV Offersen","year":"2009","unstructured":"Offersen BV, Overgaard M, Kroman N, Overgaard J. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiother Oncol. 2009;90(1):1\u201313.","journal-title":"Radiother Oncol"},{"key":"436_CR32","doi-asserted-by":"crossref","unstructured":"Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, et\u00a0al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5\u00a0years of tamoxifen. J Clin Oncol. 2008;26(12):1948\u201355. Epub 10 Mar 2008. Erratum in: J Clin Oncol. 2008;26(21):3659.","DOI":"10.1200\/JCO.2007.11.6798"},{"key":"436_CR33","doi-asserted-by":"crossref","unstructured":"Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, et\u00a0al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5\u00a0years of tamoxifen: NCIC CTG intergroup trial MA. 17. J Clin Oncol. 2008;26(12):1956\u201364. [Epub 10 Mar 2008].","DOI":"10.1200\/JCO.2007.12.6334"},{"issue":"6797","key":"436_CR34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature. 2000;406(6797):747\u201352.","journal-title":"Nature"},{"issue":"14","key":"436_CR35","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"436_CR36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nrc2173","volume":"7","author":"C Sotiriou","year":"2007","unstructured":"Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer. 2007;7(7):545\u201353.","journal-title":"Nat Rev Cancer"},{"key":"436_CR37","doi-asserted-by":"crossref","unstructured":"Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol. 2008;26(26):4360\u20131; author reply 4361\u20132.","DOI":"10.1200\/JCO.2008.18.6197"},{"key":"436_CR38","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2007.13.1748","volume":"26","author":"EA Rakha","year":"2008","unstructured":"Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568\u201381.","journal-title":"J Clin Oncol"},{"issue":"25","key":"436_CR39","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","volume":"347","author":"MJ Vijver van de","year":"2002","unstructured":"van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999\u20132009.","journal-title":"N Engl J Med"},{"key":"436_CR40","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726\u201334.","journal-title":"J Clin Oncol"},{"key":"436_CR41","doi-asserted-by":"crossref","unstructured":"Huang CC, Bredel M. Use of gene signatures to improve risk estimation in cancer. JAMA. 2008;299(13):1605\u20136.","DOI":"10.1001\/jama.299.13.1605"},{"issue":"8","key":"436_CR42","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2008.20.2812","volume":"27","author":"DH Roukos","year":"2009","unstructured":"Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol. 2009;27(8):1337\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"436_CR43","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/jnci\/djn127","volume":"100","author":"DF Hayes","year":"2008","unstructured":"Hayes DF, Stearns V, Rae J, Flockhart D. Consortium on breast cancer pharmacogenomics. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst. 2008;100(9):610\u20133.","journal-title":"J Natl Cancer Inst"},{"key":"436_CR44","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233\u201341.","journal-title":"N Engl J Med"},{"issue":"12","key":"436_CR45","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2004.04.033","volume":"22","author":"K Metcalfe","year":"2004","unstructured":"Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328\u201335.","journal-title":"J Clin Oncol"},{"key":"436_CR46","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","volume":"24","author":"LJ Pierce","year":"2006","unstructured":"Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, et al. Ten-year multiinstitutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated stage I\/II breast cancer. J Clin Oncol. 2006;24:2437\u201343.","journal-title":"J Clin Oncol"},{"issue":"7","key":"436_CR47","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.2007.12.6078","volume":"26","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26(7):1093\u20137.","journal-title":"J Clin Oncol"},{"key":"436_CR48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1245\/s10434-007-9612-4","volume":"15","author":"M Fatouros","year":"2008","unstructured":"Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1\/2 mutations. Ann Surg Oncol. 2008;15:21\u201333.","journal-title":"Ann Surg Oncol"},{"key":"436_CR49","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1200\/JCO.2005.10.035","volume":"23","author":"SA Narod","year":"2005","unstructured":"Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol. 2005;23:1656\u201363.","journal-title":"J Clin Oncol"},{"key":"436_CR50","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"key":"436_CR51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","volume":"108","author":"AR Venkitaraman","year":"2002","unstructured":"Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171\u201382.","journal-title":"Cell"},{"issue":"7","key":"436_CR52","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF02574474","volume":"9","author":"DH Roukos","year":"2002","unstructured":"Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol. 2002;9(7):607\u20139.","journal-title":"Ann Surg Oncol"},{"key":"436_CR53","doi-asserted-by":"crossref","unstructured":"Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol. 2008;26(20):3310\u20136.","DOI":"10.1200\/JCO.2006.10.3168"},{"key":"436_CR54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ng853","volume":"31","author":"PD Pharoah","year":"2002","unstructured":"Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 31:33\u20136.","journal-title":"Nat Genet"},{"key":"436_CR55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. 1994 A strong candidate for the breast and ovarian-cancer susceptibility gene BRCA1. Science. 1994;266:66\u201371.","journal-title":"Science"},{"key":"436_CR56","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789\u201392.","journal-title":"Nature"},{"key":"436_CR57","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/gcc.20354","volume":"45","author":"P Smith","year":"2006","unstructured":"Smith P, McGuffog L, Easton DF, Mann GJ, Pupo GM, Newman B, et al. A\u00a0genome wide linkage search for breast cancer susceptibility genes. Genes Chromosom Cancer. 2006;45:646\u201355.","journal-title":"Genes Chromosom Cancer"},{"issue":"6","key":"436_CR58","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1086\/522611","volume":"81","author":"AC Antoniou","year":"2007","unstructured":"Antoniou AC, Sinilnikova OM, Simard J, L\u00e9on\u00e9 M, Dumont M, Neuhausen SL, et al. RAD51 135GC modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet. 2007;81(6):1186\u2013200.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"436_CR59","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ajhg.2008.02.008","volume":"82","author":"AC Antoniou","year":"2008","unstructured":"Antoniou AC, Spurdle AB, Sinilnikova OM. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008;82(4):937\u201348.","journal-title":"Am J Hum Genet"},{"key":"436_CR60","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2007.13.8503","volume":"26","author":"K Offit","year":"2008","unstructured":"Offit K, Garber JE. Time to check CHEK2 in families with breast cancer? J Clin Oncol. 2008;26:519\u201320.","journal-title":"J Clin Oncol"},{"issue":"2","key":"436_CR61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cell.2007.01.007","volume":"128","author":"A Friedman","year":"2007","unstructured":"Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell. 2007;128(2):225\u201331.","journal-title":"Cell"},{"key":"436_CR62","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1146\/annurev.cellbio.22.010305.104154","volume":"23","author":"NA Lobo","year":"2007","unstructured":"Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol. 2007;23:675\u201399.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"1","key":"436_CR63","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","volume":"3","author":"RK Jain","year":"2006","unstructured":"Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3(1):24\u201340.","journal-title":"Nat Clin Pract Oncol"},{"issue":"26","key":"436_CR64","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666\u201376.","journal-title":"N Engl J Med"},{"key":"436_CR65","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1056\/NEJMoa071825","volume":"357","author":"A Patocs","year":"2007","unstructured":"Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med. 2007;357:2543\u201351.","journal-title":"N Engl J Med"},{"issue":"15","key":"436_CR66","first-page":"1636","volume":"358","author":"DH Roukos","year":"2008","unstructured":"Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med. 2008;358(15):1636.","journal-title":"N Engl J Med"},{"issue":"11","key":"436_CR67","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834\u201346.","journal-title":"Nat Rev Cancer"},{"key":"436_CR68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc073152","volume":"358","author":"DH Roukos","year":"2008","unstructured":"Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2008;358:197.","journal-title":"N Engl J Med"},{"key":"436_CR69","doi-asserted-by":"crossref","unstructured":"ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA, Dutta A, Guig\u00f3 R, Gingeras TR, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447(7146):799\u2013816.","DOI":"10.1038\/nature05874"},{"issue":"5858","key":"436_CR70","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1126\/science.318.5858.1843","volume":"318","author":"J Kaiser","year":"2007","unstructured":"Kaiser J. Breakthrough of the year. It\u2019s all about me. Science. 2007;318(5858):1843.","journal-title":"Science"},{"issue":"2","key":"436_CR71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMp0708162","volume":"358","author":"DJ Hunter","year":"2008","unstructured":"Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle\u2014will we get our wish? N Engl J Med. 2008;358(2):105\u20137.","journal-title":"N Engl J Med"},{"key":"436_CR72","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","volume":"20","author":"SR Lakhani","year":"2002","unstructured":"Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, 59, 60 and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310\u201318.","journal-title":"J Clin Oncol"},{"key":"436_CR73","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1078-0432.CCR-03-1061","volume":"10","author":"WD Foulkes","year":"2004","unstructured":"Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004;10:2029\u201334.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"436_CR74","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","volume":"26","author":"ND Kauff","year":"2008","unstructured":"Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331\u20137.","journal-title":"J Clin Oncol"},{"key":"436_CR75","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1172\/JCI34772","volume":"18","author":"TA Manolio","year":"2008","unstructured":"Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest. 2008;18:1590\u2013605.","journal-title":"J Clin Invest"},{"key":"436_CR76","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","volume":"358","author":"M Esteller","year":"2008","unstructured":"Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148\u201359.","journal-title":"N Engl J Med"},{"key":"436_CR77","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","volume":"349","author":"JG Herman","year":"2003","unstructured":"Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042\u201354.","journal-title":"N Engl J Med"},{"key":"436_CR78","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","volume":"92","author":"M Esteller","year":"2000","unstructured":"Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"436_CR79","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ccr.2006.04.020","volume":"9","author":"Y Saito","year":"2006","unstructured":"Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006;9:435\u201343.","journal-title":"Cancer Cell"},{"issue":"4","key":"436_CR80","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1158\/0008-5472.CAN-06-4218","volume":"67","author":"A Lujambio","year":"2007","unstructured":"Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Seti\u00e9n F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67(4):1424\u20139.","journal-title":"Cancer"},{"issue":"1","key":"436_CR81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/14737159.8.1.29","volume":"8","author":"DH Roukos","year":"2008","unstructured":"Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn. 2008;8(1):29\u201339.","journal-title":"Expert Rev Mol Diagn"},{"issue":"4","key":"436_CR82","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1245\/s10434-009-0317-8","volume":"16","author":"DH Roukos","year":"2009","unstructured":"Roukos DH. Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol. 2009;16(4):795\u2013798.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"436_CR83","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/14737159.8.5.587","volume":"8","author":"DH Roukos","year":"2008","unstructured":"Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn. 2008;8(5):587\u201397.","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"436_CR84","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1245\/s10434-008-0056-2","volume":"16","author":"DH Roukos","year":"2009","unstructured":"Roukos DH, Ziogas D. Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the \"Gordian Knot\"? Ann Surg Oncol. 2009;16(3):774\u20135","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"436_CR85","first-page":"772","volume":"16","author":"DH Roukos","year":"2009","unstructured":"Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol. 2009;16(3):772\u20133.","journal-title":"Expert Rev Mol Diagn"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-009-0436-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-009-0436-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-009-0436-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T16:08:21Z","timestamp":1684944501000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-009-0436-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,26]]},"references-count":85,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1245\/s10434-009-0436-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,26]]}}}